Gossamer Bio Inc (NASDAQ:GOSS) Major Shareholder Sells $461,470.24 in Stock
Gossamer Bio Inc (NASDAQ:GOSS) major shareholder Fund V. Gp L.P. Omega sold 21,404 shares of Gossamer Bio stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $21.56, for a total value of $461,470.24. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ GOSS opened at $21.88 on Friday. Gossamer Bio Inc has a fifty-two week low of $15.59 and a fifty-two week high of $25.06. The stock has a market cap of $1.41 billion and a price-to-earnings ratio of -0.97. The business has a fifty day moving average of $19.57 and a 200-day moving average of $19.83. The company has a quick ratio of 17.80, a current ratio of 17.80 and a debt-to-equity ratio of 0.09.
Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.18). As a group, analysts anticipate that Gossamer Bio Inc will post -2.93 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. acquired a new position in Gossamer Bio in the second quarter valued at $3,059,000. Marshall Wace North America L.P. acquired a new position in Gossamer Bio in the first quarter valued at $9,523,000. Redmile Group LLC acquired a new position in Gossamer Bio in the first quarter valued at $5,418,000. Federated Investors Inc. PA acquired a new position in Gossamer Bio in the first quarter valued at $15,992,000. Finally, Rhumbline Advisers acquired a new position in Gossamer Bio in the first quarter valued at $271,000. 54.64% of the stock is owned by institutional investors.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
See Also: Are FAANG stocks a good investment?
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.